February 12, 2021
Contact: Marti DeLay, (312) 266-7200
Series B Financing will enable European commercialization and U.S. market approval of Laser Therapy System
CHICAGO – Novian Health, developer of Novilase® Breast Therapy, announced today that it has been selected to present at the Cavendish Global Summit on February 25th. This exclusive virtual opportunity invites members to meet and hear from the latest field experts and select Cavendish Innovation Partners (https://cavendishglobal.com/summit-series/10).
“We are excited to be part of the Cavendish community,” said Henry “Chip” Appelbaum, Novian Health’s President and CEO. “With our laser technology, we hope to improve the treatment of early-stage breast cancer for women and make it more effective and less traumatic than surgery. We are making significant progress in that direction, having developed the only ablation device to receive European market approval to treat breast cancer. In the U.S., FDA approved an expedited pivotal trial to support market approval.” The Series B will allow the company to complete the trial for U.S. clearance, launch European commercial operations, bring forth a second indication to market and evaluate the immunotherapeutic benefit of laser ablation.
Cavendish summits convene their community once a month, hosting critical discussions, and showcasing groundbreaking discovers and innovations. Companies are reviewed in a rigorous process that examines the companies’ technological innovation, health impact and management strength. Cavendish is a peer-to-peer community of groundbreaking innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key experts and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformational impact.
Novilase is a laser-based, minimally invasive device for destroying tumors. It provides an alternative to conventional surgery while preserving the patient’s options for additional procedures or adjunctive therapies. The image-guided outpatient procedure does not require general anesthetic or a hospital stay.
About Novian Health
Novian Health Inc., based in Chicago with a subsidiary in Evry, France, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy. Developed as an alternative to surgery, the Company’s image-guided treatment of breast tumors is the first application of the technology, with the potential for Novilase to treat tumors elsewhere in the body. Novian Health has received a CE Mark for the focal destruction of cancerous and benign breast tumors, as well as U.S. FDA 510(k) clearance for the treatment of benign breast tumors. For more information, call (312) 266-7200 or access www.novianhealth.com.